论文部分内容阅读
目的阐述细胞色素P450 3A5基因多态性对临床药代动力学影响的研究进展。方法分析、归纳、总结发表的文献。结果与结论药物基因组学通过研究基因表达水平及单核苷酸多态性与临床药代动力学或药物毒性的相关性,增加药物的有效性和安全性,减少不良反应,因而受到广泛研究,取得了重要的进展。细胞色素P450 3A5基因的遗传多态性存在明显的个体差异,对不同个体的药物治疗作用和不良反应及药物的毒性产生重要影响,是引起个体及种族间对同一底物代谢能力不同的原因之一。目前对该基因多态性与临床药代动力学的研究主要集中在大环内酯类抗生素、抑制胃酸用药、保肝及肝病辅助药、调节血脂药、镇静催眠及抗焦虑药、免疫调节剂等药以及其他药物。
Objective To study the influence of cytochrome P450 3A5 gene polymorphism on clinical pharmacokinetics. Methods to analyze, summarize, summarize the published literature. RESULTS AND CONCLUSION Pharmacogenomics was extensively studied by studying the correlation between gene expression levels and single nucleotide polymorphisms and clinical pharmacokinetics or drug toxicity to increase the effectiveness and safety of drugs and reduce adverse reactions. Significant progress has been made. The genetic polymorphism of cytochrome P450 3A5 gene has obvious individual differences and has important influence on drug treatment and side effects of different individuals and the toxicity of drugs. It is the reason that causes the different metabolism ability of individuals and races to the same substrate one. At present, the studies on the gene polymorphism and clinical pharmacokinetics mainly focus on macrolide antibiotics, gastric acid suppressive drugs, hepatoprotective and hepatopathy adjuvant drugs, lipid-lowering drugs, sedative and hypnotic drugs and anti-anxiety drugs, immunomodulators Other drugs and other drugs.